GlassScriptPhysician profile
Suzanna Chatterjee
NPI 1942439377
$6,037.46
in general payments reported to CMS, 2019-2025
25 companies · $3,411 in 2025
The $3,411 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $69.74 · 2021: $855 · 2022: $392 · 2023: $792 · 2024: $401 · 2025: $3,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $1,565 · Travel and Lodging: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.19 |
| Education | $1,564.54 |
| Travel and Lodging | $1,168.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,036.08 | 2025 | |
| Abbvie INC. | $565.37 | 2019-2025 | Botox, Lo Loestrin Fe, Orilissa |
| Novo Nordisk INC | $471.30 | 2019-2025 | Wegovy |
| Minerva Surgical, INC | $278.61 | 2021-2025 | |
| Shield Therapeutics INC | $217.80 | 2024-2025 | |
| Merz North America, INC. | $180.53 | 2021 | |
| Hologic Sales and Service, LLC | $179.96 | 2021-2025 | Novasure, Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $146.55 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $133.89 | 2021 | |
| Galderma Laboratories, L.P. | $121.60 | 2023 | |
| Applied Medical Resources Corporation | $106.01 | 2021 | |
| Becton, Dickinson and Company | $77.16 | 2019-2024 | Bd Onclarity |
| Mayne Pharma Commercial LLC | $77.01 | 2022-2025 | |
| Exeltis, USA INC. | $65.71 | 2020-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $61.02 | 2020-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.80 | 2019-2022 | |
| Organon LLC | $36.03 | 2022-2024 | |
| Lilly USA, LLC | $33.97 | 2023-2024 | Zepbound |
| Sumitomo Pharma America, INC. | $33.18 | 2024-2025 | Myfembree |
| Astellas Pharma US INC | $31.80 | 2024 | Veozah |
| Pfizer INC. | $30.78 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $30.26 | 2019 | |
| Myovant Sciences INC. | $29.55 | 2022 | |
| Agile Therapeutics, INC. | $24.60 | 2023 | Twirla |
| Therapeuticsmd, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanna Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.